View Associated Notes
Category 6 - PATHOLOGY SERVICES
73313 - Additional Information
Development of a quantitative patient‑specific molecular assay for measurable residual disease (MRD) testing performed on bone marrow (or a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia treated with combination chemotherapy or after salvage therapy, including the first service described in item 73316 performed on that bone marrow or peripheral blood sample, requested by a specialist or consultant physician practising as a haematologist or oncologist
Applicable once per patient per episode of disease or per relapse
Fee: $3,000.00 Benefit: 75% = $2,250.00 85% = $2,901.30
(See para PN.7.20 of explanatory notes to this Category)
Associated Notes
Category 6 - PATHOLOGY SERVICES
Legend
- Assist - Addition/Deletion of (Assist.)
- Amend - Amended Description
- Anaes - Anaesthetic Values Amended
- Emsn - EMSN Change
- Fee - Fee Amended
- Renum - Item Number Change (renumbered)
- New - New Item
- NewMin - New Item (previous Ministerial Determination)
- Qfe - QFE Change